Preclinical evaluation of a novel antibody-drug conjugate targeting DR5 for lymphoblastic leukemia therapy

Acute lymphoblastic leukemia (ALL) is an aggressive hematological neoplasm resulting from immature lymphoid precursors. An antibody-drug conjugate (ADC), coupling a small molecule covalently with a targeting antibody, can specifically kill tumor cells. Death receptor 5 (DR5) is considered as a promi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shuyong, Zhou, Dongdong, Zheng, Chao, Xiong, Peng, Zhu, Wan, Zheng, Dexian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173093/
https://www.ncbi.nlm.nih.gov/pubmed/34141870
http://dx.doi.org/10.1016/j.omto.2021.04.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173093/
https://www.ncbi.nlm.nih.gov/pubmed/34141870
http://dx.doi.org/10.1016/j.omto.2021.04.013

Ejemplares similares